An Oakland biotech company has gotten its product through three first-phase clinical trials, proving the safety of a drug that the company says has wound healing, anti-inflammatory and other properties.
The topically applied product dubbed ST266, which was developed by Noveome Biotherapeutics Inc., was well tolerated for the potential treatment of skin, eye and oral health conditions, with no drug-related complications reported in phase-one trials, according to CEO Clarke Atwell.
Noveome, formerly known as Stemnion Inc., was co-founded in 2000 by William Golden and George Sing of Lancet Capital in collaboration with former UPMC transplant surgeon John Fung; George Michalopoulos, chair, department of pathology at UPMC; and others.
“We’ve seen no pattern of side effects related to the drug,” said Mr. Atwell, 49, who has led the company for about a year after a career with Merck & Co., Roche Holding AG and other pharmaceutical companies.
The company employs 47 people, mostly in Pittsburgh.
Mr. Atwell said the company would begin enrolling patients in a phase-two clinical trial this quarter, which will determine the safe dosage range in a small group of people. Drug approval through the Food and Drug Administration generally involves four clinical trials, involving as few as 20 to as many as thousands of patients, to answer specific questions about a new product, including safety and efficacy.
“We are moving very rapidly into development from research,” he said.
Protecting and regrowing nerves, cell regeneration and modulating inflammation are among the properties of ST266, the company said. For that reason, the drug has a wide range of potential uses.
In 2015 and 2014, Noveome predecessor Stemnion received contracts valued at $9 million and nearly $10 million from the U.S. Naval Medical Logistics Command in Fort Detrick, Md., for research and development services related to the Navy’s cellular combat wound initiative. Mr. Atwell said the company’s product has possible battlefield applications.
Kris B. Mamula: kmamula@post-gazette.com, or 412-263-1699





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.